Table 2.
Metabolite identification results and the difference between patient groups
| m/z | RT (min) | Metabolite | Ionospheric models | AO versus NO‡ | AY versus NY‡ | AY versus AO§ | SY versus NY‡ |
|---|---|---|---|---|---|---|---|
| 510.354 | 7.95221 | LysoPC(17:0) | M+H | Down† | Down† | Down† | – |
| 546.352 | 8.58423 | LysoPC(18:0) | M+Na | Down† | Down† | – | Down† |
| 508.375 | 8.03549 | LysoPC(P-18:0) | M+H | Down† | Down† | – | Down† |
| 506.359 | 8.58556 | LysoPC(P-18:1(9Z)) | M+H | Down† | Down† | – | Down† |
| 522.354 | 7.66455 | LysoPC(18:1(11Z)) | M+H | Down† | Down† | – | – |
| 550.386 | 8.77023 | LysoPC(20:1(11Z)) | M+H | Down† | Down† | – | Down† |
| 540.305 | 6.80829 | LysoPC(18:3(6Z,9Z,12Z)) | M+Na | Down† | Down† | Up* | – |
| 570.352 | 7.86944 | LysoPC(20:2(11Z,14Z)) | M+Na | Down† | Down† | – | Down† |
| 487.286 | 8.57992 | PA(20:4(5Z,8Z,11Z,14Z) e/2:0) | M+H | Down† | Down* | Up† | Down* |
| 556.529 | 10.4299 | Cer(t18:0/16:0) | M+H | Up† | Up† | Up* | Up* |
| 544.338 | 7.11841 | LysoPC(20:4(5Z,8Z,11Z,14Z)) | M+H | Down* | – | – | – |
| 302.305 | 6.72781 | Sphinganine | M+H | Up* | Up* | – | – |
| 356.351 | 7.40061 | Catelaidic acid | M+NH4 | Up† | Up† | – | Up* |
| 312.326 | 7.28137 | Phytal | M+NH4 | Up† | Up* | Down* | – |
| 495.248 | 4.54762 | Leukotriene D5 | M+H | Up† | – | – | – |
| 484.464 | 9.44252 | Cer(d18:0/12:0) | M+H | Up† | Up† | Up† | Up† |
| 284.294 | 6.74211 | Octadecanamide | M+H | Up† | Up† | – | – |
| 346.331 | 6.74818 | 2-hydroxyphytanic acid | M+NH4 | – | Up† | – | – |
| 118.065 | 1.75456 | Guanidoacetic acid | M+H | – | Down† | – | – |
| 270.144 | 5.74974 | Threoninyl-lysine | M+Na | – | Down† | – | Down† |
| 314.228 | 5.75407 | 9-decenoylcarnitine | M+H | – | Down† | – | – |
*P<0.05; †P<0.01; ‡Compared with control group, §Compared with AO group. Cer: Ceramide; –: No significant difference.